SINOVAC BIOTECH LTD's ticker is SVA and the CUSIP is P8696W104. A total of 32 filers reported holding SINOVAC BIOTECH LTD in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,410 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q2 2023 | $19,410 | +2.2% | 3,000 | 0.0% | 0.00% | – |
| Q3 2022 | $19,000 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q2 2022 | $19,000 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q4 2021 | $19,000 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q3 2021 | $19,000 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q2 2021 | $19,000 | 0.0% | 3,000 | 0.0% | 0.00% | – |
| Q1 2021 | $19,000 | +533.3% | 3,000 | +650.0% | 0.00% | – |
| Q3 2020 | $3,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | 0.0% | 400 | -29.1% | 0.00% | – |
| Q1 2017 | $3,000 | -62.5% | 564 | -60.2% | 0.00% | – |
| Q4 2016 | $8,000 | -70.4% | 1,416 | -68.6% | 0.00% | – |
| Q3 2016 | $27,000 | +800.0% | 4,506 | +763.2% | 0.00% | – |
| Q2 2016 | $3,000 | -40.0% | 522 | -33.2% | 0.00% | – |
| Q1 2016 | $5,000 | +66.7% | 781 | +39.2% | 0.00% | – |
| Q4 2015 | $3,000 | – | 561 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,718,735 | $340,500,000 | 6.32% |
| Vivo Capital, LLC | 5,900,000 | $38,173,000 | 4.21% |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2,042 | 0.72% |
| Yorktown Management & Research Co Inc | 74,893 | $485,000 | 0.63% |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259,000 | 0.00% |
| Renaissance Technologies | 2,375,841 | $1,537,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 1,687 | $11,000 | 0.00% |
| NORTHERN TRUST CORP | 13,787 | $55,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 412 | $27,000 | 0.00% |